Navigation Links
North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India
Date:11/27/2009

DURHAM, N.C., Nov. 27 /PRNewswire/ -- Cromoz Inc., located in Research Triangle Park, will initiate water-soluble carbon nanotube-based cancer drug delivery system in Hyderabad, India. The water-soluble carbon nanotubes, which have functional groups on the walls that allows for conjugation with cancer drugs, was developed in partnership with the Indian Institute of Kanpur (ITT). The conjugated carbon nanotubes serves as a drug delivery vehicle with the ability to target the cancer site which has the potential to increase the drug efficacy.

The target drug delivery reduces the amount of chemotherapeutic drugs used in cancer treatment and minimizes the side effects. The reduced dosage without compromising the drug efficacy will make the cancer treatment more potent and targeted to killing the cancer and more affordable and available to a larger community.

"Certain percentage of these carbon nanotubes are composed of smaller Quantum Carbon Dots," stated Iffat Allam, President & CEO of Cromoz Inc. "The nontoxic carbon quantum dots can be used as Fluorescent Probes for imaging living biological processes and to monitor cancer growth. These quantum dots are of assorted sizes, they absorb and emit light at different wavelengths. This results in multi-colored images which will be very useful to diagnose a specific organ and its function and the effect of drug delivery to specific cancer sites."

Cromoz has successfully conjugated cancer drugs such as Taxol and Gemcitabine and is currently working with Johns Hopkins Cancer Center in Maryland, USA. Early next year Cromoz will initiate a research and development (R&D) and manufacturing facility in Biotech Park in Hyderabad, India.

Cromoz Inc., is an advanced materials innovator and manufacturer focused on the development of carbon nanotechnology-enabled products primarily for the biomedical industry. These innovative products are based on two proprietary technologies, water-soluble carbon nanotubes and water-soluble fluorescent carbon quantum dots. The CNTs (Carbon Nano Tubes) are insoluble in water. Some have used a common technique to wrap the CNT with hydrophilic molecules to make them disperse in water. Cromoz have successfully derivatized the multi-wall of CNTs and Carbon Dots to make them water-soluble. These derivatized CNTs are bio-friendly, fluorescent and hence well suited for drug delivery. For more information, log on to http://www.cromoz.com.


Contact:

Anita L. Jackson, MD: 910-258-5480 or adocalj@aol.com
Mr. Ashfaq Hussein: 099-7122-1940 or info@cnanoz.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

SOURCE Cromoz Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India
2. North America automobile sector bottom of world sustainability league
3. North Highland Ranks in Top Five of Consulting Industrys Best Firms to Work For
4. Northeast Indiana Regional Partnership to Participate in 2009 Orthopedic Design & Technology Conference & Exhibition
5. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
6. Cord Blood America Announces Preferred Pricing for Blue Cross of Northeastern Pennsylvania Members
7. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
8. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
9. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
10. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
11. Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):